MedCity and Life Science Incubation Council join forces to enhance life sciences sector between London and Japan
09 October 2024
- New partnership aims to foster talent and knowledge exchange
- Commencing ahead of UK delegation at BioJapan 2024
MedCity, London’s life sciences cluster, and Life Science Incubation Council, the organisation leading Japan’s life sciences sector, have announced a strategic partnership.
Aimed at advancing the life sciences sector between London and Japan, the collaboration is set to commence at BioJapan 2024 – Asia’s largest annual biotech exhibition, held in Yokohama from the 9th to the 11th of October 2024, starting with a joint seminar focused on the unique strengths of Japanese innovation within a global ecosystem.
The partnership will establish talent exchange programmes to enable scientists, researchers, and industry professionals to work together on joint research initiatives and exchange knowledge.
The collaboration will also create new opportunities for investment in life sciences startups and projects in both markets, encouraging cross-border funding, joint R&D and support for innovative businesses.
Dr. Angela Kukula, CEO of MedCity, said: “London and Japan are both global leaders in Life Sciences, so I’m really excited to partner with Life Sciences Incubation Council to strengthen and extend our interactions. I am confident that it will be a fruitful partnership. I am looking forward to seeing how we can open new avenues for research and development that, will not only benefit both our local communities, but also accelerate investment and innovation in health and life sciences globally.”
MedCity and Life Science Incubation Council will co-host industry events, conferences, and workshops to foster networking, knowledge sharing, and collaboration among stakeholders in the life sciences sector.
Commenting on this, Nao Yoshizawa, Founder of the Life Science Incubation Council added: “Life Science Incubation Council and MedCIty have been working together in the various occasions in the past. Thanks to the new strategic partnership, we will step into the next phase to collaborate more widely and deeply for the development of the life science sector both in Japan and UK.
We are seeking for the opportunities such as for joint R&D projects between two countries. We also hope to develop the platform for Japanese start-ups to learn more on the advanced start-up ecosystem run by MedCity, which will lead to the globalization of the Japanese life science sector as a whole.”
For more information about MedCity, visit: MedCityHQ.com. For more information about
London & Partners, visit: www.londonandpartners.com.
Notes to editors
Notes to Editors
About MedCity
MedCity is part of London & Partners, the growth agency for London. Its mission is to create economic growth that is resilient, sustainable, and inclusive. It a social enterprise, half funded by the Greater London Authority (GLA) and half from other sources including our portfolio of commercial ventures.
MedCity works to accelerate investment and innovation in health and life sciences in London by promoting the sector and strengthening connections within the ecosystem.
From working with biotech, medtech, pharma companies, and the broader life sciences ecosystem, MedCity’s goal is to supercharge innovation, drive inward investment, and build skills and talent across the sectors in the UK. Working in close partnership with London’s world-leading universities and national ecosystem stakeholders, MedCity creates powerful networks and partnerships to fast-track R&D, with a specialist focus on diagnostics and cell and gene therapy.
For more information about MedCity, visit: MedCityHQ.com or on X @MedCityHQ.
About Life Science Incubation Council
Life Science Incubation Council (LSIC), run by Willsame Inc, was officially established in September 2022. Primary objective of LSIC is to develop the platform and ecosystem, on which industry players, academia, start-ups, CDMO, CMO, professional service providers and governments work together, to foster the creative innovation in the life science sector,
LSIC is also engaging in the seeds and needs matching activities for the novel drug discovery and innovative medical device development. Assisting the researchers in the academia and start-ups LSIC proceeds the open innovation program in partnership with industry players.
LSIC is expanding the global network, including MedCIty, through the collaboration to facilitate the cross-border R&D activities, which leads to the globalization of the Japanese life science industry.
For more information, please visit: https://lsic.jp/en/ or contact Toshi Seki, Global Alliance Director (t.seki@will-same.com).
Contact
Emma Johnson-Ferguson
Email:ejohnson-ferguson@londonandpartners.comLondon & Partners Media & PR Team
Tel:+44 (0)20 7234 5710
Tel:+44 (0)20 7234 5800
Email:press@londonandpartners.com